MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development - Seite 2
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising five Phase 2
studies (two led by GSK), two Phase 1 studies, four pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and Galapagos signed a worldwide license agreement whereby AbbVie will be responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has another selective
JAK1 inhibitor in Phase 2 in ulcerative colitis and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program
has completed a Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class
molecule that targets inflammatory disorders and has completed Phase 1. GLPG1690 is a first-in-class compound that targets pulmonary diseases and is currently in a Phase 1 study. AbbVie
and Galapagos signed an agreement in CF whereby they work collaboratively to develop and commercialize oral drugs that address two mutations in the CFTR gene, the G551D and F508del mutation.
Potentiator GLPG1837 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium
headquarters and facilities in The Netherlands, France, and Croatia. Further information at: www.glpg.com
For more information, please contact:
MorphoSys AG | Galapagos NV |
Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Mario Brkulj Associate Director Corporate Communications & IR Alexandra Goller Specialist Corporate Communications & IR Jessica Rush Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com |
Elizabeth Goodwin, Head of Corporate Communications & IR Tel. +31 6 2291 6240 ir@glpg.com |
Lesen Sie auch
HuCAL®, HuCAL GOLD®, HuCAL
PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered
trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
SilenceSelect® is a registered trademark of Galapagos NV